We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ICER Finds Treatments for Cardiovascular Disease Cost-Effective
ICER Finds Treatments for Cardiovascular Disease Cost-Effective
In its latest cost-benefit analysis, the Institute for Clinical and Economic Review (ICER) found that Janssen’s Xarelto (rivaroxaban) and Amarin Pharma’s Vascepa (icosapent ethyl) are cost-effective treatments for cardiovascular disease — provided not all eligible patients are treated.